CMIT has consistently aligned with China Merchants Group's strategic layout and approach for technological innovation amid its "Third Entrepreneurship" initiative. It is speeding up the development of the Sci-tech Innoation Industry Sector, vigorously advancing technological innovation, and forging an efficient "industry-university-research-application" collaborative innovation model—all while accelerating breakthroughs in a range of major industrial cutting-edge technologies, disruptive technologies, and key core technologies. Pioneering the establishment of three major research platforms—the "Synthetic Biotechnology Innovation Center," "Cell and Gene Therapy Innovation Center," and "Artificial Intelligence Innovation Center"—it is refining the industry-university-research collaborative innovation R&D system. Meanwhile, it prioritizes driving Tianjin Institute of Pharmaceutical Research to deliver on synthetic biology goals: "2 compounds, 3 target products, and 3 manufacturing processes".